Crocs Raises Earnings Guidance Amid Direct Sales Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2024
0mins
Source: WSJ
Crocs Inc's stock rose 4.76% as it reached a 20-day high, reflecting positive market conditions with the Nasdaq-100 up 1.52% and the S&P 500 up 0.47%.
The company raised its full-year earnings guidance to approximately $13.48 per share after reporting a 13% increase in direct-to-consumer sales in Q1. Despite challenges with its HeyDude brand, which saw a 12% revenue decline, Crocs' international sales growth, particularly in markets like China and India, has alleviated concerns about saturation in North America. This strong performance in direct sales and international markets indicates potential for brand transformation and investor confidence.
The implications of this earnings guidance raise optimism among investors, suggesting that Crocs is adapting well to market challenges and could present an attractive entry point for those believing in the strength of its core brand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CROX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CROX
Wall Street analysts forecast CROX stock price to fall
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 125.780
Low
75.00
Averages
88.71
High
100.00
Current: 125.780
Low
75.00
Averages
88.71
High
100.00
About CROX
Crocs, Inc. is engaged in the design, development, worldwide marketing, distribution, and sale of casual lifestyle footwear and accessories for all. The Company's brands include Crocs and HEYDUDE. The Crocs Brand's collection contains Croslite material, a proprietary, molded footwear technology. It also uses Croslite material formulations in connection with material technologies used in its visible comfort collections, such as its LiteRide and Free Feel Technology products. The HEYDUDE Brand offers shoes with an iconic and versatile loafer silhouette for many wearing occasions that focus on casualization, comfort-led functionality and personalization. It sells its products in more than 85 countries, through wholesale and direct-to-consumer channels. Its wholesale channel includes domestic and international multi-brand retailers, e-tailers and others. Its direct-to-consumer channel includes Company-operated retail stores, Company-operated e-commerce sites and third-party marketplaces.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Software Stocks Rally as Moderna Surges 11% on Long-Term Strategy
- Software Sector Strength: Despite a broader tech sector decline, the iShares Expanded Tech-Software Sector ETF (IGV) rose by 3%, with Microsoft and Salesforce both gaining over 4%, indicating strong market confidence in software companies that may drive future investment inflows.
- Moderna's Strategic Shift: Moderna's stock surged 11% after detailing its long-term strategy at its annual Science Day, expanding beyond vaccines to include mRNA-based oncology and rare disease treatments, showcasing its potential for growth in the biotech sector.
- Healthcare Sector Rally: The S&P 500 healthcare sector outperformed, rising over 2%, with Veeva Systems and Eli Lilly both up 7%, reflecting increased investor confidence in the healthcare industry and signaling potential growth opportunities ahead.
- ON Semiconductor's Acquisition: ON Semiconductor announced a nearly $7 billion all-stock deal to acquire Synaptics, resulting in a 23% stock drop, yet it is expected to increase the company's total addressable market by $30 billion, highlighting its strategic expansion intentions in the semiconductor industry.
See More
Major Wall Street Rating Changes on Friday
- Diageo Upgrade: TD Cowen upgraded Diageo from hold to buy, citing valuation dislocation as an attractive entry point, with CEO-led cost cuts and reinvestment expected to restore growth and enhance commercial execution.
- James Hardie Initiation: Stephens initiated coverage of James Hardie with an overweight rating and a $31 price target, highlighting its status as a high-quality company and its position as the second-largest composite decking manufacturer following its merger with AZEK.
- Nike Downgrade: KeyBanc downgraded Nike from overweight to sector weight, indicating that the turnaround is taking longer than anticipated, with slight reductions in FY27 estimates reflecting higher-than-expected headwinds in China and EMEA.
- American Tower Upgrade: RBC upgraded American Tower from sector perform to outperform, noting superior organic revenue growth compared to peers, despite rising interest rate pressures, indicating strong market potential.
See More
Nasdaq Futures Lead Wall Street Losses Amid Chip Stock Pressure
- Chip Stock Pressure: Micron Technology (MU.O) shed 4.8% in premarket trading after a more than 15% rally the previous session, indicating market concerns over high valuations that could impact the broader tech sector's performance.
- Large Tech Volatility: While Apple (AAPL.O) shares remained steady after a more than 6% drop on Thursday due to price hikes, Tesla (TSLA.O) and Alphabet (GOOGL.O) also faced declines, reflecting a divergence in market sentiment towards megacap stocks.
- Market Sentiment Weighed Down: Reports of OpenAI considering delaying its public debut negatively impacted risk sentiment in the tech space, particularly affecting software companies like Salesforce (CRM.N) and ServiceNow (NOW.N), which each rose around 1% on Friday amid concerns that AI could disrupt their business models.
- Fed Rate Hike Expectations: With the new chairman in place, concerns about the Federal Reserve hiking interest rates linger, as traders price in a 25-basis-point hike and a near 27% chance of another by year-end, highlighting uncertainty in future economic policies.
See More
Wall Street Analysts Weekly Recap: Crocs, PTC, Oscar, General Dynamics
- Crox Target Upgrade: Baird upgrades Crocs Inc (NASDAQ:CROX) to Outperform with a $150 price target, reflecting management's confidence in North America and HEYDUDE, anticipating low-single-digit revenue growth by 2026, showcasing resilience amid a challenging retail environment.
- PTC Strong Performance: Citi rates PTC Therapeutics Inc (NASDAQ:PTCT) as Buy with a $108 target, driven by the successful U.S. launch of its PKU drug Sephience, projecting $980 million in revenue, highlighting significant market potential and underappreciated pipeline candidates.
- Oscar Health Upgrade: Barclays upgrades Oscar Health Inc (NYSE:OSCR) to Overweight with a $35 target, emphasizing its focused exposure to the Individual ACA market, which is expected to lead to a substantial valuation rerating, projecting a 13x to 15x P/E ratio.
- General Dynamics Positive Outlook: Jefferies upgrades General Dynamics Corporation (NYSE:GD) to Buy with a $400 target, based on strong demand in naval shipbuilding and a $125 billion government defense plan, anticipating a steady revenue stream and long-term shareholder value.
See More
Crocs Partners with SuperOrdinary for TikTok Microdrama Launch
- Innovative Marketing Strategy: Crocs has partnered with SuperOrdinary to launch the first U.S. footwear brand TikTok microdrama series, 'Déjà Shoe,' which integrates TikTok Shop product tagging to directly link products, aiming to enhance engagement and conversion among younger consumers.
- Strong Stock Performance: Currently, Crocs trades at $124.71, with a 4.5% increase over the past week, 28.7% over the past month, and 43.4% year-to-date, indicating robust market momentum that investors should monitor for future social commerce performance.
- Potential Growth Opportunities: This microdrama project not only tests entertainment-driven shopping models but also presents direct sales opportunities for Crocs, especially given its large online audience, suggesting that future marketing strategies could significantly influence e-commerce approaches.
- Risk Monitoring: Despite Crocs' strong stock performance, attention should be paid to risks such as high debt and recent insider selling, with management expected to discuss key metrics like TikTok Shop traffic, conversion rates, and customer acquisition costs in future updates.
See More
Crocs Stock Up 50% After Analyst Upgrade
- Analyst Upgrade: Baird analyst Jonathan Komp upgraded Crocs from 'neutral' to 'outperform' and raised the price target from $115 to $150, reflecting increased confidence in the brand's recovery in North America, which could drive further stock price appreciation.
- Sales Growth Momentum: Crocs' international sales rose 7% last quarter to $421 million, while direct-to-consumer revenue increased by 13% to $322 million, indicating improving brand performance in North America that may support future earnings.
- HeyDude Brand Challenges: Despite Crocs' overall strong performance, HeyDude's revenue fell 12% last quarter to $154 million, with wholesale revenue plunging 25%, highlighting ongoing challenges in the brand's restructuring that could impact overall performance.
- Optimistic Earnings Outlook: Analysts forecast Crocs' adjusted earnings per share to reach $13.55 this year, with potential to approach $17 by 2027 if sales accelerate and share buybacks increase, indicating significant growth potential for the company.
See More
Software Stocks Rally as Moderna Surges 11% on Long-Term Strategy
- Software Sector Strength: Despite a broader tech sector decline, the iShares Expanded Tech-Software Sector ETF (IGV) rose by 3%, with Microsoft and Salesforce both gaining over 4%, indicating strong market confidence in software companies that may drive future investment inflows.
- Moderna's Strategic Shift: Moderna's stock surged 11% after detailing its long-term strategy at its annual Science Day, expanding beyond vaccines to include mRNA-based oncology and rare disease treatments, showcasing its potential for growth in the biotech sector.
- Healthcare Sector Rally: The S&P 500 healthcare sector outperformed, rising over 2%, with Veeva Systems and Eli Lilly both up 7%, reflecting increased investor confidence in the healthcare industry and signaling potential growth opportunities ahead.
- ON Semiconductor's Acquisition: ON Semiconductor announced a nearly $7 billion all-stock deal to acquire Synaptics, resulting in a 23% stock drop, yet it is expected to increase the company's total addressable market by $30 billion, highlighting its strategic expansion intentions in the semiconductor industry.
See More
Major Wall Street Rating Changes on Friday
- Diageo Upgrade: TD Cowen upgraded Diageo from hold to buy, citing valuation dislocation as an attractive entry point, with CEO-led cost cuts and reinvestment expected to restore growth and enhance commercial execution.
- James Hardie Initiation: Stephens initiated coverage of James Hardie with an overweight rating and a $31 price target, highlighting its status as a high-quality company and its position as the second-largest composite decking manufacturer following its merger with AZEK.
- Nike Downgrade: KeyBanc downgraded Nike from overweight to sector weight, indicating that the turnaround is taking longer than anticipated, with slight reductions in FY27 estimates reflecting higher-than-expected headwinds in China and EMEA.
- American Tower Upgrade: RBC upgraded American Tower from sector perform to outperform, noting superior organic revenue growth compared to peers, despite rising interest rate pressures, indicating strong market potential.
See More
Nasdaq Futures Lead Wall Street Losses Amid Chip Stock Pressure
- Chip Stock Pressure: Micron Technology (MU.O) shed 4.8% in premarket trading after a more than 15% rally the previous session, indicating market concerns over high valuations that could impact the broader tech sector's performance.
- Large Tech Volatility: While Apple (AAPL.O) shares remained steady after a more than 6% drop on Thursday due to price hikes, Tesla (TSLA.O) and Alphabet (GOOGL.O) also faced declines, reflecting a divergence in market sentiment towards megacap stocks.
- Market Sentiment Weighed Down: Reports of OpenAI considering delaying its public debut negatively impacted risk sentiment in the tech space, particularly affecting software companies like Salesforce (CRM.N) and ServiceNow (NOW.N), which each rose around 1% on Friday amid concerns that AI could disrupt their business models.
- Fed Rate Hike Expectations: With the new chairman in place, concerns about the Federal Reserve hiking interest rates linger, as traders price in a 25-basis-point hike and a near 27% chance of another by year-end, highlighting uncertainty in future economic policies.
See More
Wall Street Analysts Weekly Recap: Crocs, PTC, Oscar, General Dynamics
- Crox Target Upgrade: Baird upgrades Crocs Inc (NASDAQ:CROX) to Outperform with a $150 price target, reflecting management's confidence in North America and HEYDUDE, anticipating low-single-digit revenue growth by 2026, showcasing resilience amid a challenging retail environment.
- PTC Strong Performance: Citi rates PTC Therapeutics Inc (NASDAQ:PTCT) as Buy with a $108 target, driven by the successful U.S. launch of its PKU drug Sephience, projecting $980 million in revenue, highlighting significant market potential and underappreciated pipeline candidates.
- Oscar Health Upgrade: Barclays upgrades Oscar Health Inc (NYSE:OSCR) to Overweight with a $35 target, emphasizing its focused exposure to the Individual ACA market, which is expected to lead to a substantial valuation rerating, projecting a 13x to 15x P/E ratio.
- General Dynamics Positive Outlook: Jefferies upgrades General Dynamics Corporation (NYSE:GD) to Buy with a $400 target, based on strong demand in naval shipbuilding and a $125 billion government defense plan, anticipating a steady revenue stream and long-term shareholder value.
See More
Crocs Partners with SuperOrdinary for TikTok Microdrama Launch
- Innovative Marketing Strategy: Crocs has partnered with SuperOrdinary to launch the first U.S. footwear brand TikTok microdrama series, 'Déjà Shoe,' which integrates TikTok Shop product tagging to directly link products, aiming to enhance engagement and conversion among younger consumers.
- Strong Stock Performance: Currently, Crocs trades at $124.71, with a 4.5% increase over the past week, 28.7% over the past month, and 43.4% year-to-date, indicating robust market momentum that investors should monitor for future social commerce performance.
- Potential Growth Opportunities: This microdrama project not only tests entertainment-driven shopping models but also presents direct sales opportunities for Crocs, especially given its large online audience, suggesting that future marketing strategies could significantly influence e-commerce approaches.
- Risk Monitoring: Despite Crocs' strong stock performance, attention should be paid to risks such as high debt and recent insider selling, with management expected to discuss key metrics like TikTok Shop traffic, conversion rates, and customer acquisition costs in future updates.
See More
Crocs Stock Up 50% After Analyst Upgrade
- Analyst Upgrade: Baird analyst Jonathan Komp upgraded Crocs from 'neutral' to 'outperform' and raised the price target from $115 to $150, reflecting increased confidence in the brand's recovery in North America, which could drive further stock price appreciation.
- Sales Growth Momentum: Crocs' international sales rose 7% last quarter to $421 million, while direct-to-consumer revenue increased by 13% to $322 million, indicating improving brand performance in North America that may support future earnings.
- HeyDude Brand Challenges: Despite Crocs' overall strong performance, HeyDude's revenue fell 12% last quarter to $154 million, with wholesale revenue plunging 25%, highlighting ongoing challenges in the brand's restructuring that could impact overall performance.
- Optimistic Earnings Outlook: Analysts forecast Crocs' adjusted earnings per share to reach $13.55 this year, with potential to approach $17 by 2027 if sales accelerate and share buybacks increase, indicating significant growth potential for the company.
See More
